Lincoln Pharmaceuticals Ltd — Nov 2025 Quarterly Analysis

1. VERDICT & BUSINESS QUALITY SNAPSHOT

The punchline. Read this first — it frames everything below.

Result: Weak Miss **One-line:** Revenue growth has decelerated to a stagnant 5% while EBITDA margins compressed by 260 bps, making the "□1,000 Cr revenue" target increasingly reliant on the elusive commencement of EU/Australia exports.

Dimension	This Quarter	Signal / Evidence	Sentiment
Beat/Miss vs Guidance / Prior Quarter	Weak Miss	FY25 revenue growth (5.0%) significantly trailed the 15-18% internal target.	□
Earnings Quality	High (Core driven)	Net profit of □82.44 Cr is purely operational; no major one-offs noted.	□
Guidance Confidence	Weak	Achieving □1,000 Cr in 3 years requires a 15.6% CAGR—triple the current growth rate.	□
Management Credibility	Neutral	Successfully maintained 'Net Debt Free' status but failed to deliver promised growth.	□
Business Quality Signal	Deteriorating	ROCE fell from 21.8% to 19.2%; PAT margins compressed to 12.3% (multi-year low).	□
Key Q&A Exchange	N/A — PPT_ONLY	No concall conducted/available.	□
The Street's Primary Anxiety	Execution Delay	When will high-margin exports to regulated markets (EU/Canada/Australia) scale?	□
Capital Cycle Stage	Expansion	Investing in Unit 3 (Mehsana) for OSD and Dry Powder Injection.	□
Margin / Return Ratio Trajectory	Deteriorating	Continuous YoY decline in EBITDA and PAT margins since FY24.	□
Pricing Power	Eroding	Margin contraction despite a 62% export mix suggests pricing pressure in semi-regulated markets.	□
FCF Conversion & Quality	Not in document	Cash flow statement not provided in PPT.	□
Competitive Moat Signals	Stable	EU-GMP and TGA certifications remain solid barriers to entry for regulated markets.	□
Balance Sheet Strength	Strong	Net Cash surplus increased to □13.4 Cr; effectively zero insolvency risk.	□
Working Capital Efficiency	Stable	Net debt-free status suggests disciplined working capital management.	□
Mgmt Guidance Track Record	Mixed	5-year CAGR of ~10% is respectable but significantly lower than forward-looking claims.	□
Key Vulnerability / Red Flag	R&D Starvation	R&D spend as % of sales has collapsed from 3.2% (FY18) to 1.7% (FY25).	□
Management Tone	Confident	PPT focuses on "high-value product lines" and "Global Footprints."	□

Sentiment: □Neutral

Key Takeaways (Positives & Negatives): * **Positives:** Lincoln maintains a "Fortress Balance Sheet" with □13.4 Cr in net cash and zero debt. The domestic portfolio is pivoting toward higher-value chronic segments (Diabetes/Cardiac) with the launch of the Vonolink (Vonoprazan) and Glypanta (Empagliflozin) series. Certifications (EU-GMP, TGA) for its facilities are active, keeping the regulated market option open. * **Negatives:** Operational momentum is stalling. A 5% top-line growth for a small-cap pharma player is insufficient, especially when accompanied by a 260 bps contraction in EBITDA margins (now 19.2%). The multi-year decline in R&D intensity (now just 1.7% of sales) raises serious questions about the sustainability of the "innovative" NDDS pipeline management frequently cites. * **The Street's Concern:** Investors are frustrated by the timeline of regulated market launches. While infrastructure is ready, the P&L impact remains absent, leaving the company exposed to the lower-margin, volatile semi-regulated African and Asian markets. * **Forward Watchpoint:** The specific commencement date of commercial shipments to France (EU) and Australia (TGA). Without these, the margin trajectory will likely remain subdued.

---

2. BUSINESS PERFORMANCE

2A. KEY METRICS

DATA SOURCE: Concall not available — commentary absent.

Metric	Current Qtr (FY25)	YoY Change	QoQ Change	Trend	Mgmt Commentary
India Revenue	□244.72 Cr	+5.8%	N/A	↑	Focus on cardiac, diabetic, and ENT segments.
Export Revenue	□400.99 Cr	+4.5%	N/A	↑	Presence in 60+ countries; EU/TGA "imminent."
Total Revenue	□645.71 Cr	+5.0%	N/A	↑	Growth driven by high-value product entry.
EBITDA	□123.97 Cr	-7.7%	N/A	↓	Margins impacted by cost/mix headwinds.
EBITDA Margin %	19.2%	-260 bps	N/A	↓	Down from 21.8% in FY24.
PAT	□82.44 Cr	-11.7%	N/A	↓	Contraction outpaced revenue growth.
ROCE (%)	19.2%	-260 bps	N/A	↓	Significant drop from prior year efficiency.
Net Debt / (Cash)	(□13.4 Cr)	-□7.6 Cr	N/A	↑	Net cash surplus increased (Improved).
R&D Pipeline	30+ Scientists	N/A	N/A	→	R&D Spend dropped to 1.7% of sales.
Book Value / Share	□335.35 (implied)	+13.3%	N/A	↑	Net worth grew to □671.7 Cr.

2B. SEGMENT BREAKDOWN

Segment	Revenue (□ Cr)	YoY Growth	Margin	Trend	vs Company Avg	Key Development
Exports	□400.99	+4.5%	High	→	Above Avg	Presence in 60+ countries; EU-GMP certified.
Domestic	□244.72	+5.8%	Stable	→	Below Avg	Expansion into chronic (Cardiac/Diabetes).

---

3. MANAGEMENT OUTLOOK & EXECUTION TRACKER

Dimension	Category	Management Target / Claim	Required Run-Rate / Mathematical Feasibility	Historical Delivery	Risk Flag
Guidance	Revenue	₹1,000 Cr within 3 years	Needs 15.6% CAGR from FY25 base.	**Missed:** FY25 growth (5%) vs target (15-18%).	High
Guidance	Margins	Maintain healthy margins	Requires EBITDA recovery to >21% levels.	**Missed:** Margins compressed to 19.2%.	Medium
Guidance	Market Entry	Entry into Regulated Markets	Commercial volumes from EU/Australia needed.	Certifications in place; volumes pending.	High
Strategy	R&D	Focus on Innovations/NDDS	R&D spend is only 1.7% of sales.	**Declining:** Spend % has halved since FY18.	High
Balance	Leverage	Maintain Net Debt Free status	No debt on books; Net Cash increased.	**Met:** Consistently net debt free.	Low

4. ANALYST Q&A

Section not applicable — investor presentation only. No concall conducted or available.

5. WHAT CHANGED vs PRIOR QUARTER

What Changed	Prior Quarter (FY24)	This Quarter (FY25)	Direction
Revenue Growth Rate	15.4% YoY	5.0% YoY	↓
EBITDA Margin	21.8%	19.2%	↓
PAT Margin	15.7%	12.3%	↓
Net Cash Surplus	₹5.8 Cr	₹13.4 Cr	↑
ROCE	21.8%	19.2%	↓
R&D Intensity	1.9% of Sales	1.7% of Sales	↓
Domestic Focus	Cardiac/ENT	Chronic (Vonoprazan/Empagliflozin)	→
Required Growth Math	~13.5% CAGR for target	~15.6% CAGR for target	↓ (Harder)

STOP HERE.